Figure 3.
PFS of select bridging therapies and select first-line therapies after CAR-T failure. Median PFS is depicted to the right of each individual regimen. Ab, antibody; PolaBR, polatuzumab + bendamustine + rituximab.
PFS of select bridging therapies and select first-line therapies after CAR-T failure. Median PFS is depicted to the right of each individual regimen. Ab, antibody; PolaBR, polatuzumab + bendamustine + rituximab.
